Clinical trial
A Safety and Efficacy Study of Intetumumab, Alone and in Combination With…
NCT00246012 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00246012 |
|---|---|
| Title | A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma |
| Official title | A Phase 1/2, Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human α ν Integrins (CNTO 95), Alone and in Combination With Dacarbazine, in Subjects With Stage IV Melanoma |
| Lead sponsor | Centocor, Inc., Industry |
| Collaborators | Janssen-Cilag Farmaceutica, S.R.L. |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Intetumumab, Dacarbazine, Placebo |
| Enrollment | 144 |
| Start date | May 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Feb 1, 2009 |
| First posted | Oct 31, 2005 |
| Last update posted | Aug 19, 2013 |
| Countries | Germany, United Kingdom, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: